Home - Products - Apoptosis - Apoptosis - Pamrevlumab

Pamrevlumab

CAS No. 946415-13-0

Pamrevlumab( —— )

Catalog No. M36727 CAS No. 946415-13-0

Pamrevlumab (FG-3019) is a human antibody with affinity for connective tissue growth factor (CTGF) and is involved in anti-CTGF therapy for the treatment of idiopathic pulmonary fibrosis (IPF).

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	392	In Stock
10MG	629	In Stock
25MG	938	In Stock
50MG	1274	In Stock
100MG	Get Quote	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Pamrevlumab
Note

Research use only, not for human use.
Brief Description

Pamrevlumab (FG-3019) is a human antibody with affinity for connective tissue growth factor (CTGF) and is involved in anti-CTGF therapy for the treatment of idiopathic pulmonary fibrosis (IPF).
Description

FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF).
In Vitro

——
In Vivo

——
Synonyms

——
Pathway

Apoptosis
Target

Apoptosis
Recptor

Apoptosis
Research Area

——
Indication

——

Chemical Information

CAS Number

946415-13-0
Formula Weight
Molecular Formula

——
Purity

>98% (HPLC)
Solubility

——
SMILES

——
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1. Sgalla G, et, al. Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. 2020 Aug;29(8):771-777.?

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

related products

ZINC69391

ZINC69391 is a selective inhibitor of Rac1 with antiproliferative and antimetastatic effects. ZINC69391 interferes with the interaction of Rac1 with Dock180, reduces Rac1-GTP levels and induces apoptosis.
N-Hexanoyl-D-sphingo...

C6-ceramide, a ceramide pathway activator, shows activity against a variety of cancer cell lines. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects.
Puromycin aminonucle...

Puromycin aminonucleoside increases podocyte permeability by modulating ZO-1 in an oxidative stress-dependent manner.Puromycin aminonucleoside -induced podocyte apoptosis is p53 dependent. Puromycin aminonucleoside causes podocyte apoptosis in a time-dependent manner.

Sign In Join Free